Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vitamin D3

This article was originally published in The Tan Sheet

Executive Summary

FDA grants approval for use of higher vitamin D3 levels as a nutrient supplement in cheese and cheese products, according to a final rule published in the Federal Register Nov. 16. Approval was granted following a food additive petition submitted by Kraft Foods. The petition requested that the previously allowed levels of vitamin D (89 IU per 100 g) be increased to 81 IU per 30 g. To support the safety of the proposed levels, Kraft submitted dietary intake estimates from current and proposed uses and from naturally occurring sources of vitamin D and compare the intake estimates to the tolerable upper intake level for vitamin D established by the Institute of Medicine, FDA notes. Use of vitamin D3 in certain meal replacement bars and beverages was approved in June by FDA in response to a citizen petition filed by Slim-Fast marketer Unilever (1"The Tan Sheet" July 4, 2005, p. 15)...

You may also be interested in...

Vitamin D3 Approved For Meal Replacement Beverages, Bars

FDA approved vitamin D3 as a food additive in certain functional foods for weight management in a final rule effective June 29

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts